Retatrutide represents a promising advancement in pharmacologic therapy for obesity, offering potential for greater weight reduction than currently available GLP-1 RAs, although long-term safety and real-world effectiveness remain under investigation. This evidence concerns the gene GLP1R and obesity disorder.